Understanding the Impact of Anti-TNF-α Therapy on Inflammatory Bowel Disease
Anti-tumor necrosis factor alpha (anti-TNF-α) agents have significantly altered the landscape of treatment for moderate-to-severe inflammatory bowel disease (IBD), providing new hope for patients grappling with these chronic conditions. Yet, challenges such as primary non-response, secondary loss of response, and access-related barriers persist, particularly in resource-limited environments. This study aimed to scrutinize the real-life effectiveness of anti-TNF-α therapy in patients with IBD receiving care at a tertiary gastroenterology center in Morocco, while also shedding light on the clinical and access-related obstacles that could affect treatment outcomes.
Study Overview and Findings
Conducted in the Department of Gastroenterology and Hepatology at Mohammed VI University Hospital in Marrakech from September 2019 to March 2024, this retrospective, single-center study involved 79 patients diagnosed with either Crohn’s disease (CD) or ulcerative colitis (UC). The demographic analysis revealed a mean age of 36 years among participants, with a notable gender distribution of 54% male and 46% female. Notably, 76% of the cohort had CD, while 24% were diagnosed with UC. The data highlighted severe disease characteristics, with 51.6% of CD patients experiencing ileocolonic involvement and a significant 56.6% suffering from perianal lesions.
The study employed a descriptive analytical approach, collecting comprehensive data from medical records, which included demographic details, clinical profiles, treatment regimens, and outcomes. The findings indicated that infliximab was the most commonly utilized anti-TNF-α agent, prescribed to 71% of patients, followed by adalimumab and golimumab. Moreover, a combination therapy with azathioprine was observed in 57% of patients, aiming to enhance treatment efficacy and mitigate immunogenicity.
After a mean follow-up of 30 months, the investigation revealed a primary non-response rate of 19% and a secondary loss of response rate of 22.8%. Various management strategies were implemented for treatment failures, including dose optimization, intra-class switching, and, in some cases, surgical interventions. Unfortunately, financial constraints led to treatment discontinuation in 22.8% of patients, emphasizing the pressing need for improved access to biologic therapies in resource-constrained settings. Furthermore, 7.6% of patients were lost to follow-up, which highlights a significant limitation in the retrospective study design.
The results of this study underscore the real-life effectiveness of anti-TNF-α therapy, even amid a high prevalence of severe IBD phenotypes. However, the challenges posed by primary non-response and secondary loss of response remain significant hurdles. The presence of severe clinical features and access-related barriers must be considered crucial factors influencing long-term treatment outcomes. To optimize patient care in resource-limited environments, close monitoring, individualized management plans, and enhanced access to biologic therapies are essential.
As reported by cureus.com.
